Arbutus Biopharma Corp
ABUS
查看详细走势图
4.780USD
-0.010-0.21%
收盘 12/26, 16:00（美东）报价延迟15分钟
917.54M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.21%
5天
+7.90%
1月
+8.39%
6月
+49.38%
今年开始到现在
+46.18%
1年
+48.91%
查看详细走势图
TradingKey Arbutus Biopharma Corp股票评分
单位: USD 更新时间: 2025-12-26操作建议
Arbutus Biopharma Corp当前公司基本面数据相对健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名73/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.67。中期看，股价处于平稳状态。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Arbutus Biopharma Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
3
位分析师
买入
评级
5.667
目标均价
+25.37%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Arbutus Biopharma Corp亮点
亮点风险
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
业绩增长期
公司处于发展阶段，最新年度总收入6.17M美元
估值低估
公司最新PE估值-21.66，处于3年历史低位
机构加仓
最新机构持股120.46M股，环比增加0.01%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值14.77K
Arbutus Biopharma Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Arbutus Biopharma Corp简介
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
公司代码ABUS
公司Arbutus Biopharma Corp
CEOAndroski (Lindsay)
网址https://www.arbutusbio.com/
常见问题
Arbutus Biopharma Corp(ABUS)的当前股价是多少？
Arbutus Biopharma Corp(ABUS)的当前股价是 4.780。
Arbutus Biopharma Corp的股票代码是什么？
Arbutus Biopharma Corp的股票代码是ABUS。
Arbutus Biopharma Corp股票的52周最高点是多少？
Arbutus Biopharma Corp股票的52周最高点是5.100。
Arbutus Biopharma Corp股票的52周最低点是多少？
Arbutus Biopharma Corp股票的52周最低点是2.705。
Arbutus Biopharma Corp的市值是多少？
Arbutus Biopharma Corp的市值是917.54M。
Arbutus Biopharma Corp的净利润是多少？
Arbutus Biopharma Corp的净利润为-69.92M。
现在Arbutus Biopharma Corp(ABUS)的股票是买入、持有还是卖出？
根据分析师评级，Arbutus Biopharma Corp(ABUS)的总体评级为买入，目标价格为5.667。
Arbutus Biopharma Corp(ABUS)股票的每股收益（EPS TTM）是多少
Arbutus Biopharma Corp(ABUS)股票的每股收益（EPS TTM）是-0.221。
相关品种
